EMA Authorised: Voraxaze (glucarpidase) — SERB SAS

View source ↗

Summary

EU authorities authorised Voraxaze (glucarpidase) for use in treating methotrexate toxicity with delayed clearance, and granted orphan medicine designation to S…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Delayed Methotrexate Clearance
• Methotrexate Toxicity

Drugs mentioned

• Voraxaze (glucarpidase)

Snippet

Status: Authorised. Therapeutic area: Metabolic Side Effects of Drugs and Substances. MAH: SERB SAS. Decision date: 05/12/2025. Orphan medicine